Our CEO, Dr. Vladimir Cmiljanovic, answered these and many more questions about the challenges of developing a safe and effective SARS-CoV-2 vaccine in RocketVax for PRVA TV:
In the process of developing our vaccine against SARS-CoV-2, our experts in RocketVax use coronavirus-based vectors that carry all the coronavirus’s immunogenic features but cannot reproduce, making the particles non-infectious.
A digital DNA design platform ensures the novel vaccine vectors’ easy design and streamlined production. Utilizing highly sophisticated algorithms, we have generated custom-designed synthetic viral genomes packed into attenuated yet authentic virus particles.
These particles can be continuously produced in a highly controlled process using well-characterized cell lines.
Follow our LinkedIn, Instagram, and Facebook page to keep up with our progress.